初始抗CD19嵌合抗原受体T细胞疗法对复发/难治性大B细胞淋巴瘤患者后续抗CD22嵌合抗原受体T细胞制备及临床结局的影响
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.
作者信息
Su Yi-Jiun, Kramer Anne Marijn, Hamilton Mark P, Agarwal Neha, Srinagesh Hrishikesh K, Baird John H, Sahaf Bita, Kuo Adam, Ehlinger Zachary J, Desai Moksha H, Rietberg Skyler P, Tunuguntla Ramya, Patel Shabnum, Chinnasamy Harshini, Gkitsas-Long Nikolaos, Klysz Dorota D, Brown Annie Kathleen, Bharadwaj Sushma, Dahiya Saurabh, Smith Melody, Muffly Lori, Mackall Crystal L, Good Zinaida, Feldman Steven A, Miklos David B, Frank Matthew J
机构信息
Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, California.
Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan.
出版信息
Cancer Discov. 2025 Apr 2;15(4):733-747. doi: 10.1158/2159-8290.CD-24-1071.
Abstract
Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.
摘要
晚期白细胞单采术（嵌合抗原受体19 [CAR19] 后>6个月）导致残留的CAR19较少、CAR22 CD4+初始T细胞和中央记忆T细胞较多、效应记忆T细胞较少以及CD8+中央记忆T细胞较多，但临床结果与早期白细胞单采术相似。CAR22反应与更高的转导效率、CD8+中央记忆T细胞以及更少的CD8+效应记忆T细胞相关。
相似文献
1
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL.初始抗CD19嵌合抗原受体T细胞疗法对复发/难治性大B细胞淋巴瘤患者后续抗CD22嵌合抗原受体T细胞制备及临床结局的影响
Cancer Discov. 2025 Apr 2;15(4):733-747. doi: 10.1158/2159-8290.CD-24-1071.
2
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.CD22 导向的 CAR T 细胞疗法治疗 CD19 导向的 CAR T 细胞疗法后进展的大 B 细胞淋巴瘤：一项剂量探索性 1 期研究。
Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9.
3
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.CRISPR/Cas9技术构建的通用型CD19/CD22双靶点嵌合抗原受体T细胞疗法治疗复发/难治性B细胞急性淋巴细胞白血病
Clin Cancer Res. 2021 May 15;27(10):2764-2772. doi: 10.1158/1078-0432.CCR-20-3863. Epub 2021 Feb 24.
4
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.嵌合抗原受体 T 细胞靶向 CD19 和 CD22 治疗成人复发性或难治性 B 细胞恶性肿瘤：一项 1 期试验。
Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26.
5
CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.CD22 导向的 CAR T 细胞疗法可诱导 CD19 导向的 CAR 难治性大 B 细胞淋巴瘤完全缓解。
Blood. 2021 Apr 29;137(17):2321-2325. doi: 10.1182/blood.2020009432.
6
Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.双特异性 CAR-T 细胞靶向 CD19 和 CD22 治疗复发或难治性 B 细胞急性淋巴细胞白血病成人患者。
J Hematol Oncol. 2020 Apr 3;13(1):30. doi: 10.1186/s13045-020-00856-8.
7
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.异基因移植后复发的 B 细胞急性淋巴细胞白血病的 CD19 和 CD22 CAR-T 细胞治疗的联合应用。
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
8
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.一项评估 NKTR-255 联合 CD19-22 CAR T 细胞治疗难治性 B 细胞急性淋巴细胞白血病的 1 期临床试验。
Blood. 2024 Oct 17;144(16):1689-1698. doi: 10.1182/blood.2024024952.
9
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.异基因CD19/CD22嵌合抗原受体T细胞疗法治疗B细胞急性淋巴细胞白血病
JAMA Oncol. 2024 Jun 1;10(6):821-824. doi: 10.1001/jamaoncol.2024.0473.
10
Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.工程化新型CD19/CD22双靶点嵌合抗原受体T细胞以增强抗肿瘤活性。
Cancer Invest. 2022 Mar;40(3):282-292. doi: 10.1080/07357907.2021.2005798. Epub 2021 Nov 25.
引用本文的文献
1
CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.针对CD19导向免疫治疗后复发的B细胞急性淋巴细胞白血病儿童和成人的CD22靶向嵌合抗原受体修饰T细胞
J Immunother Cancer. 2025 Apr 17;13(4):e011549. doi: 10.1136/jitc-2025-011549.
本文引用的文献
1
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.CD22 导向的 CAR T 细胞疗法治疗 CD19 导向的 CAR T 细胞疗法后进展的大 B 细胞淋巴瘤：一项剂量探索性 1 期研究。
Lancet. 2024 Jul 27;404(10450):353-363. doi: 10.1016/S0140-6736(24)00746-3. Epub 2024 Jul 9.
2
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.通过外周血免疫表型监测 CAR19 可揭示组织学特异性扩增和毒性。
Blood Adv. 2024 Jun 25;8(12):3314-3326. doi: 10.1182/bloodadvances.2024012637.
3
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).ZUMA-7 二线治疗大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞疗法的产品属性与疗效和毒性的差异关联
Blood Cancer Discov. 2024 Jan 8;5(1):21-33. doi: 10.1158/2643-3230.BCD-23-0112.
4
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.TRANSCEND NHL 001 研究中接受乐西妥珠单抗治疗的复发/难治性大 B 细胞淋巴瘤患者的 2 年随访结果
Blood. 2024 Feb 1;143(5):404-416. doi: 10.1182/blood.2023020854.
5
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.嵌合抗原受体 T 细胞作为嵌合抗原受体 T 细胞治疗失败后的挽救疗法。
Transplant Cell Ther. 2023 Sep;29(9):574.e1-574.e10. doi: 10.1016/j.jtct.2023.06.019. Epub 2023 Jun 30.
6
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.阿基仑赛治疗大 B 细胞淋巴瘤的总生存。
N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5.
7
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome.免疫效应细胞相关性噬血细胞性淋巴组织细胞增生症样综合征。
Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. doi: 10.1016/j.jtct.2023.03.006. Epub 2023 Mar 9.
8
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 的 5 年随访结果支持 axi-cel 在难治性大 B 细胞淋巴瘤中的治疗潜力。
Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893.
9
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.自体抗 BCMA 嵌合抗原受体 T 细胞（liso-cel）治疗二线弥漫大 B 细胞淋巴瘤（DLBCL）的 3 期 TRANSFORM 研究的主要分析结果
Blood. 2023 Apr 6;141(14):1675-1684. doi: 10.1182/blood.2022018730.
10
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.戈利木单抗治疗复发/难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2022 Dec 15;387(24):2220-2231. doi: 10.1056/NEJMoa2206913. Epub 2022 Dec 11.
Zotero 插件